A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Sapanisertib (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Glioblastoma; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- 22 Jul 2019 Planned primary completion date changed from 30 Jun 2019 to 31 Dec 2019.
- 05 Mar 2019 Planned primary completion date changed from 31 Dec 2018 to 30 Jun 2019.
- 17 Dec 2018 Planned number of patients changed from 23 to 58.